DexamethasoneSCBPBsNCT07399691
Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery
An observational study of Dexamethasone and Bupivacaine, run by Arsi University at 1 site in Ethiopia.
Trial summary
SCBPBs provides optimal conditions for procedures performed below the mid-upper arm (elbow, forearm, wrist, hand) due to its high success rate and ease of access. Dexamethasone, when administered perineurally as an adjuvant for a supraclavicular block, demonstrated early onset of sensory and motor block, a prolonged… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Dexamethasone, Bupivacaine, Upper Limb Surgery
- What is being tested?
- Dexamethasone 8 mg
- How many people
- 54 participants
- Where
- 1 siteEthiopia
- Study dates
- 1 Jan 2024to 30 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: The study included 54 patients aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular bloc
Who may be able to join
- Aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular block.
Who cannot join
- Patients who refused, used local anaesthetics other than bupivacaine, had multiple traumas, addition of another additive, bleeding disorders, patients diagnosed with chronic pain, cancer pain, local infection at the injection site, history of local anaesthetic allergy, patients with anxiety, and inability to comprehend or use the pain rating scale
Trial locations and contacts
1 site in 1 country.
About this study
- SCBPBs provides optimal conditions for procedures performed below the mid-upper arm (elbow, forearm, wrist, hand) due to its high success rate and ease of access.
- Dexamethasone, when administered perineurally as an adjuvant for a supraclavicular block, demonstrated early onset of sensory and motor block, a prolonged duration of sensory and motor block, and a lower number of rescue analgesics as compared to bupivacaine alone.
- A combination of dexamethasone and bupivacaine is paramount in adult orthopeadic patient to enhance the efficacy of pain management under ultrasound-guided supraclavicular brachial plexus block.
- Conditions
- Dexamethasone, Bupivacaine, Upper Limb Surgery
- Being tested
- Dexamethasone 8 mg
- Keywords
- dexamethasone,Bupivacaine,Analgesia,supraclavicular block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dexamethasone 8 mgDrug
Adding 8 mg of dexamethasone to bupivacaine for ultrasound-guided supraclavicular block
| Study group | Role | What they receive |
|---|---|---|
| Group DB | Patients received a supraclavicular brachial plexus block with dexamethasone 2 ml (8 mg) added to 38 ml of 0.25 % bupivacaine. Receives: Drug: Dexamethasone 8 mg | |
| Group B | Patients received a supraclavicular brachial plexus block with 40 ml of 0.25 % bupivacaine alone. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The onset of sensory and motor blockade, and the duration of sensory and motor blockade in minutes.
- The onset of sensory: the period between injecting a study solution and losing sensation to a pinprick at every nerve distribution
- The onset of motor block: The duration between the injection of the study solution and paresis in every nerve distribution.
- duration of sensory: the period between the onset of a sensory block and the complete restoration of sensation.
- Duration of motor block: the period between the onset of a motor block and the complete restoration of motor function.
Measured: with in the first 24hrs after procedure
Secondary outcomes (2)
postoperative pain score by a visual analogue scale
This assesses behavioural or subjective phenomena by having the participant choose an alternative from a gradient ranging from 0 = (no pain) to 100 = worst possible pain. Based on the VAS score, 0-20 mm = no pain; 21-40 mm = mild pain; 41-60 mm = moderate pain; 61-80 mm = severe pain; and 81-100 mm = the worst pain imaginable
Measured: with in the first 24 hrs after procedure
First analgesic request time
The first postoperative period, when patients require pain treatment if the visual analogue score is>4
Measured: With in the first 24 hrs after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2026
- Study start1 Jan 2024
- Primary completion30 Apr 2024
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DexamethasoneStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Arsi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Gebi, Arsi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07399691
- Sponsor's protocol ID
- No-A/CHS/RC/19/2023
- Acronym
- SCBPBs
- Status last verified
- Feb 2026
- First submitted
- 23 Jan 2026
- Last updated
- 10 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery
- ClinicalTrials.gov ID
- NCT07399691
- Acronym / sponsor ID
- SCBPBs / No-A/CHS/RC/19/2023
- Conditions
- Dexamethasone, Bupivacaine, Upper Limb Surgery
- Keywords
- dexamethasone,Bupivacaine,Analgesia,supraclavicular block
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Arsi UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 10 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- SCBPBs provides optimal conditions for procedures performed below the mid-upper arm (elbow, forearm, wrist, hand) due to its high success rate and ease of access.
- Dexamethasone, when administered perineurally as an adjuvant for a supraclavicular block, demonstrated early onset of sensory and motor block, a prolonged duration of sensory and motor block, and a lower number of rescue analgesics as compared to bupivacaine alone.
- A combination of dexamethasone and bupivacaine is paramount in adult orthopeadic patient to enhance the efficacy of pain management under ultrasound-guided supraclavicular brachial plexus block.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group DB | – | Drug: Dexamethasone 8 mgPatients received a supraclavicular brachial plexus block with dexamethasone 2 ml (8 mg) added to 38 ml of 0.25 % bupivacaine. |
| Group B | – | –Patients received a supraclavicular brachial plexus block with 40 ml of 0.25 % bupivacaine alone. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The study included 54 patients aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular bloc
Key inclusion criteria (1 listed)
- Aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular block.
Key exclusion criteria (1 listed)
- Patients who refused, used local anaesthetics other than bupivacaine, had multiple traumas, addition of another additive, bleeding disorders, patients diagnosed with chronic pain, cancer pain, local infection at the injection site, history of local anaesthetic allergy, patients with anxiety, and inability to comprehend or use the pain rating scale
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexamethasone 8 mgAdding 8 mg of dexamethasone to bupivacaine for ultrasound-guided supraclavicular block | Drug | Group DB |
Primary outcome
The onset of sensory and motor blockade, and the duration of sensory and motor blockade in minutes.
Time frame: with in the first 24hrs after procedure
1. The onset of sensory: the period between injecting a study solution and losing sensation to a pinprick at every nerve distribution 2. The onset of motor block: The duration between the injection of the study solution and paresis in every nerve distribution. 3. duration of sensory: the period between the onset of a sensory block and the complete restoration of sensation. 4. Duration of motor block: the period between the onset of a motor block and the complete restoration of motor function.
2 secondary outcomes
postoperative pain score by a visual analogue scale
Time frame: with in the first 24 hrs after procedure
First analgesic request time
Time frame: With in the first 24 hrs after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Dexamethasone
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
RecruitingPhase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingPhase 3
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Not yet recruitingPhase 4
Effect of Prophylactic Dexamethasone vs Placebo on Airway Dimensions Assessed by Ultrasonography in Patients Undergoing Laparoscopic Cholecystectomy
Airway Edema, Postoperative Complications
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dexamethasone and Bupivacaine, run by Arsi University at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The onset of sensory and motor blockade, and the duration of sensory and motor blockade in minutes. (time frame: with in the first 24hrs after procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.